View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 28, 2021

Novartis and Molecular Partners commence Covid-19 treatment trial

Based on preliminary EMPATHY trial data, Novartis will file for expedited approval from the US FDA. 

Novartis and Molecular Partners have commenced Phase II/III EMPATHY clinical trial of a new DARPin therapeutic candidate, ensovibep (MP0420), to treat Covid-19.

These clinical trials will be carried out by Novartis while Molecular Partners will fund the studies.

The global, multi-centre EMPATHY trial programme is assessing the safety and efficacy of ensovibep in adult patients in the initial stages of Covid-19 infection to prevent symptom deterioration and hospitalisation.

Approximately 400 subjects will be enrolled in the Phase II part, which will determine the optimal dose based on safety and activity. Preliminary results from this study are expected in August.

Subsequently, the Phase III part will enrol 1,700 subjects and results are set to be available in the first half of next year.

On obtaining satisfactory preliminary results from the EMPATHY trial, Novartis plans to pursue expedited approval through the US Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA).

Molecular Partners CEO Patrick Amstutz said: “By virtue of its tri-specific design, ensovibep was built to resist viral mutations and indeed shows potent inhibition of all variants of concern to date, with the potential to maintain activity also for future variants.

“This type of broad-spectrum activity is essential for any treatment of relevance for patients with Covid-19.”

In March, Molecular Partners reported preliminary data from the Phase I trial, which showed ensovibep was safe and well-tolerated with no substantial adverse events in healthy subjects.

Novartis and Molecular Partners entered a collaboration in the form of an option and licence agreement for the latter’s anti-Covid-19 DARPin programme in October last year.

Through this partnership, Novartis received an option to in-license worldwide rights of Molecular Partners’ DARPin antiviral therapeutic candidates, ensovibep and MP0423, against Covid-19.

Currently, ensovibep is also being analysed in the US National Institute of Health-sponsored (NIH) ACTIV-3 Trial. This global trial is evaluating the therapeutic’s safety and efficacy in nearly 1,000 adult patients hospitalised with Covid-19.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy